Thumbnail Image
Publication

A Phase 2/3 multicenter, randomized, open-label study of lenalidomide vs investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma.

Czuczman, M
; 
Trněný, M
; 
Davies, A
; 
Rule, S
; 
Linton, Kim M
; 
Wagner-Johnston, N
; 
Gascoyne, R
; 
Slack, G
; 
Brousset, P
; 
Eberhard, D
... show 10 more
Citations
Altmetric:
Abstract
Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Authors
Czuczman, M
Trněný, M
Davies, A
Rule, S
Linton, Kim M
Wagner-Johnston, N
Gascoyne, R
Slack, G
Brousset, P
Eberhard, D
Hernandez-Ilizaliturri, F
Salles, G
Witzig, T
Zinzani, Pier L
Wright, G
Staudt, L
Yang, Y
Williams, P
Lih, C
Russo, J
Thakurta, A
Hagner, P
Fustier, P
Song, D
Lewis, I
Affiliation
Charles University HospitalCancer Research UK Centre, Somers Cancer Research Building, University of Southampton
Description
Date
2017-04-05
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
4127.full.pdf
Adobe PDF, 547.36 KB
Keywords
Type
Article
Citation
A Phase 2/3 multicenter, randomized, open-label study of lenalidomide vs investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma.. 2017 Clin Cancer Res
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620424
Embedded videos